



# In Vitro Activity of Gepotidacin (GSK2140944) against *Neisseria gonorrhoeae*

D. J. Farrell,<sup>a\*</sup> H. S. Sader,<sup>a</sup> P. R. Rhomberg,<sup>a</sup> N. E. Scangarella-Oman,<sup>b</sup> R. K. Flamm<sup>a</sup>

JMI Laboratories, North Liberty, Iowa, USA<sup>a</sup>; GlaxoSmithKline, Collegeville, Pennsylvania, USA<sup>b</sup>

**ABSTRACT** Gepotidacin (formerly GSK2140944) is a novel, first-in-class, triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV via a unique mechanism and has demonstrated *in vitro* activity against *Neisseria gonorrhoeae*, including drug-resistant strains, and also targets pathogens associated with other conventional and biothreat infections. Broth microdilution was used to evaluate the MIC and minimum bactericidal concentration (MBC) activity of gepotidacin and comparators against 25 *N. gonorrhoeae* strains (including five ciprofloxacin-nonsusceptible strains). Gepotidacin activity was also evaluated against three *N. gonorrhoeae* strains (including a ciprofloxacin-nonsusceptible strain) for resistance development, against three *N. gonorrhoeae* strains (including two tetracycline- and azithromycin-nonsusceptible strains) using time-kill kinetics and checkerboard methods, and against two *N. gonorrhoeae* strains for the investigation of postantibiotic (PAE) and subinhibitory (PAE-SME) effects. The MIC<sub>50</sub> and MIC<sub>90</sub> for gepotidacin against the 25 *N. gonorrhoeae* isolates tested were 0.12 and 0.25 μg/ml, respectively. The MBC<sub>50</sub> and MBC<sub>90</sub> for gepotidacin were 0.25 and 0.5 μg/ml, respectively. Gepotidacin was bactericidal, and single-step resistance selection studies did not recover any mutants, indicating a low rate of spontaneous single-step resistance. For combinations of gepotidacin and comparators tested using checkerboard methods, there were no instances where antagonism occurred and only one instance of synergy (with moxifloxacin; fractional inhibitory concentration, 0.375). This was not confirmed by *in vitro* time-kill studies. The PAE for gepotidacin against the wild-type strain ranged from 0.5 to >2.5 h, and the PAE-SME was >2.5 h. These *in vitro* data indicate that further study of gepotidacin is warranted for potential use in treating infections caused by *N. gonorrhoeae*.

**KEYWORDS** *Neisseria gonorrhoeae*, minimum bactericidal activity, postantibiotic effect

*Neisseria gonorrhoeae* causes a range of sexually transmitted diseases and is the second most reported notifiable infectious disease in the United States (1). *N. gonorrhoeae* is known to facilitate the acquisition of HIV infection (2). The incidence of infection caused by *N. gonorrhoeae* in the United States is currently estimated at 820,000 cases per year, with an estimated yearly health care cost of \$162 million (1).

*N. gonorrhoeae* has proven to be very adept at developing resistance to antimicrobials used to treat gonococcal disease. After penicillin resistance became prevalent, fluoroquinolones became a mainstay of treatment until resistance emerged in this class in the early to mid-2000s (3), leaving only cephalosporins as a treatment option in the United States. However, declining cefixime susceptibility was found to correlate with treatment failures (4) and, in 2012, oral cephalosporins were no longer recommended for treatment in the United States (5). In addition, it has been found that azithromycin resistance has coevolved with cephalosporin resistance, hence compromising combi-

Received 22 September 2016 Returned for modification 7 November 2016 Accepted 22 December 2016

Accepted manuscript posted online 9 January 2017

**Citation** Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. 2017. *In vitro* activity of gepotidacin (GSK2140944) against *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother* 61:e02047-16. <https://doi.org/10.1128/AAC.02047-16>.

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to R. K. Flamm, robert-flamm@jmlabs.com.

\* Present address: D. J. Farrell, Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada.

**TABLE 1** Summary of MIC<sub>50/90</sub> values, MBC<sub>50/90</sub> values, and MBC/MIC ratios for gepotidacin and ceftriaxone against 25 *N. gonorrhoeae* strains

MIC or MBC/MIC ratio	Gepotidacin	Ceftriaxone
MIC ( $\mu\text{g/ml}$ )		
MIC <sub>50</sub>	0.12	0.002
MIC <sub>90</sub>	0.25	0.008
MBC <sub>50</sub>	0.25	0.002
MBC <sub>90</sub>	0.5	0.008
MBC/MIC ratio <sup>a</sup>		
MBC <sub>50</sub> /MIC <sub>50</sub>	2	1
MBC <sub>90</sub> /MIC <sub>90</sub>	2	1

<sup>a</sup>All isolates exhibited an MBC/MIC ratio of  $\leq 4$ .

nation therapy with these two classes of antibiotics (6). Faced with an already limited and potentially complete lack of treatment options in the future, there is an urgent need to research and develop new antimicrobial agents to treat gonococcal infections.

Gepotidacin (formerly GSK2140944) is a novel, first-in-class, triazaacenaphthylene antibacterial that selectively inhibits bacterial DNA gyrase and topoisomerase IV by a unique mechanism, one that is not utilized by any currently approved human therapeutic agent. Structural data with a type IIA topoisomerase enzyme, DNA gyrase, has revealed the novel binding mode of the triazaacenaphthylene class and has distinguished it from the binding mode of the quinolone antibacterials (7). As a consequence of its novel mode of action, gepotidacin is active *in vitro* against target pathogens carrying resistance determinants to established antibacterials, including fluoroquinolones (8). Gepotidacin has demonstrated *in vitro* activity against key pathogens, including drug-resistant strains, associated with a range of conventional and biothreat infections (8).

In the present study, *in vitro* methods were used to evaluate the MIC/MBC activity of gepotidacin and comparator agents against *N. gonorrhoeae*. Gepotidacin *in vitro* activity was also evaluated for resistance development and using time-kill kinetics, for broth microdilution checkerboard methods for synergy testing, and for postantibiotic effects.

## RESULTS

**Quality control.** The recommended method for *N. gonorrhoeae* susceptibility testing is an agar dilution method (9). Quality control criteria for gepotidacin against *N. gonorrhoeae* by agar dilution have been proposed at 0.25 to 1  $\mu\text{g/ml}$  (10, 11). In the present study, the MIC values for gepotidacin for the quality control strain (*N. gonorrhoeae* ATCC 49226) were 0.5  $\mu\text{g/ml}$  when tested on agar for the resistance development analysis and 0.12 to 0.25  $\mu\text{g/ml}$  when tested in fastidious broth (FB). Quality control results for ceftriaxone were all within published Clinical and Laboratory Standards Institute (CLSI) ranges (11).

**MIC/MBC studies.** The MIC<sub>50/90</sub> for gepotidacin against 25 *N. gonorrhoeae* isolates selected for this study was 0.12/0.25  $\mu\text{g/ml}$  (Table 1). The highest gepotidacin MIC value was 0.25  $\mu\text{g/ml}$ . The ceftriaxone MIC<sub>50</sub> and MIC<sub>90</sub> for the *N. gonorrhoeae* isolates were 0.002 and 0.008  $\mu\text{g/ml}$ . The MBC<sub>50/90</sub> for gepotidacin against 25 *N. gonorrhoeae* isolates selected for this study was 0.25/0.5  $\mu\text{g/ml}$ . The highest gepotidacin MBC value was 1  $\mu\text{g/ml}$ . The ceftriaxone MBC<sub>50/90</sub> for the *N. gonorrhoeae* isolates was 0.002/0.008  $\mu\text{g/ml}$ . Gepotidacin was bactericidal when tested against *N. gonorrhoeae*, with a total of 100% (25/25) of isolates exhibiting an MBC/MIC ratio of  $\leq 4$ . For 80% (20/25) of the isolates tested, the MBC/MIC ratio was  $\leq 2$ . Ceftriaxone was bactericidal against *N. gonorrhoeae*, with a total of 100% (25/25) of the *N. gonorrhoeae* isolates tested exhibiting an MBC/MIC ratio of  $\leq 2$  (Table 1).

**Frequency of single-step resistance development.** The MIC values for gepotidacin against the three *N. gonorrhoeae* strains tested ranged from 0.25 to 0.5  $\mu\text{g/ml}$  (Table 2). The ciprofloxacin MIC value for *N. gonorrhoeae* isolate 12 was 16  $\mu\text{g/ml}$ , with a


**TABLE 2** Summary of MIC values and mutation rates for ciprofloxacin and gepotidacin for three *N. gonorrhoeae* strains

Isolate	Ciprofloxacin agar MIC ( $\mu\text{g/ml}$ )	Ciprofloxacin mutation frequency	Gepotidacin baseline agar MIC ( $\mu\text{g/ml}$ )	Gepotidacin mutation frequency
12	16 <sup>a</sup>	$<1.25 \times 10^{-9}$	0.25	$<1.25 \times 10^{-9}$
MS11	0.004	$<9.09 \times 10^{-10}$	0.5	$<9.09 \times 10^{-10}$
ATCC 49266	0.004	$<9.09 \times 10^{-10}$	0.5	$<9.09 \times 10^{-10}$


<sup>a</sup>Isolate 12 was determined to have the following genotype: GyrA S91F and D95A mutations and a ParC S87R mutation.

corresponding gepotidacin MIC value of 0.25  $\mu\text{g/ml}$  (Table 2). This isolate was determined to have the following genotype: GyrA (S91F, D95A) and ParC (S87R) mutations. The ciprofloxacin MIC value for *N. gonorrhoeae* isolates MS11 and ATCC 49226 was 0.004  $\mu\text{g/ml}$ . The MIC values for the three *N. gonorrhoeae* strains tested ranged from 0.004 to 0.015  $\mu\text{g/ml}$  for ceftriaxone, 0.25 to 2  $\mu\text{g/ml}$  for azithromycin, and 0.12 to 1  $\mu\text{g/ml}$  for tetracycline (data not shown). No mutants were observed for gepotidacin, ciprofloxacin, ceftriaxone, azithromycin, or tetracycline against any of the three strains tested. These results show a spontaneous single-step mutation rate among these *N. gonorrhoeae* strains to be less than  $1.25 \times 10^{-9}$  for gepotidacin (Table 2).

**Time-kill studies.** Figure 1 shows the *in vitro* time-kill activity of gepotidacin against *N. gonorrhoeae* isolate 12584, which was nonsusceptible to both azithromycin and tetracycline. Against this isolate, gepotidacin was bactericidal at 4 $\times$  MIC at the 8-h time point. At 10 $\times$  MIC, gepotidacin was bactericidal at the 4-h time point. Figure 2 shows the *in vitro* time-kill activity of gepotidacin against a second isolate of *N. gonorrhoeae* (12588), which was also nonsusceptible to both azithromycin and tetracycline. Gepotidacin was bactericidal against this isolate at the 24-h time point at both 4 $\times$  and 10 $\times$  MICs. No regrowth for gepotidacin was seen for either isolate. Figure 3 shows the *in vitro* time-kill activity of gepotidacin against a wild-type reference isolate of *N. gonorrhoeae*, ATCC 49226. Gepotidacin was bactericidal against this isolate at 24 h at 2 $\times$ , 4 $\times$ ,




**FIG 1** Time-kill curve for gepotidacin against *N. gonorrhoeae* (isolate 12584).



**FIG 2** Time-kill curve for gepotidacin against isolate *N. gonorrhoeae* (isolate 12588).

and 10× MICs. No regrowth for gepotidacin was noted. No colonies grew on the gepotidacin 4× MIC agar screen plates inoculated from the 24-h time point time-kill curve tubes containing either 2×, 4×, or 10× MIC gepotidacin concentrations for any of the 3 *N. gonorrhoeae* isolates tested.



**FIG 3** Time-kill curve for gepotidacin against isolate *N. gonorrhoeae* ATCC 49226.

**TABLE 3** PAE results for time-kill curves for gepotidacin and comparator agents after 1 h of exposure at 1×, 5×, and 10× baseline MIC values

<i>N. gonorrhoeae</i> isolate	Gepotidacin			Ceftriaxone				
	Baseline MIC (μg/ml)	PAE (h) at various MICs			Baseline MIC (μg/ml)	PAE (h) at various MICs		
		1×	5×	10×		1×	5×	10×
ATCC 49226	0.25	0.5	1.0	>2.5	0.004	0.3	0.0	0.0
12584	0.12	0.7	0.7	0.7	0.004	0.7	0.2	0.0

**Determination of interactions (checkerboard) evaluation.** For all of the combinations of gepotidacin and comparators tested *in vitro* against *N. gonorrhoeae*, there were no occurrences of antagonism, and there was only one occurrence of synergy (data not shown). For the remaining combinations, indifference was noted for 80.0% of *in vitro* checkerboard results, and 13.3% of results could not be determined due to off-scale MIC values (data not shown). There was one occurrence of synergy (fractional inhibitory concentration [FIC] index, 0.375) for gepotidacin tested in combination with moxifloxacin against *N. gonorrhoeae* strain 12588). To further confirm this synergy, an *in vitro* time-kill study was performed with various concentrations of gepotidacin and moxifloxacin. This *in vitro* time-kill study did not confirm the potential synergy noted in the *in vitro* checkerboard testing.

**Determination of postantibiotic and subinhibitory effects.** Against the wild-type reference strain (ATCC 49226), the PAE-SME value for gepotidacin was >2.5 h at 0.25× MIC and 0.5× MIC. The PAE-SME values for ceftriaxone were 0.5 h at 0.25× MIC and 0.1 h at 0.5× MIC (Tables 3 and 4).

Against the tetracycline- and azithromycin-nonsusceptible strain (isolate 12584), the PAE-SME values for gepotidacin were 1.2 h at 0.25× MIC and 2.7 h at 0.5× MIC. The PAE-SME values for ceftriaxone were 1.3 h at 0.25× MIC and 0.0 h at 0.5× MIC (Tables 3 and 4).

**DISCUSSION**

In the present study, gepotidacin was shown to be active (MIC<sub>50/90</sub> value of 0.12/0.25 μg/ml) and bactericidal against *N. gonorrhoeae* (MBC/MIC ratios of ≤4 against 100% of isolates tested), including strains nonsusceptible to penicillin, ciprofloxacin, and tetracycline. *In vitro* resistance selection studies indicated a low rate of mutational resistance with gepotidacin. Gepotidacin also demonstrated bactericidal activity in time-kill curves against *N. gonorrhoeae*, including isolates that were nonsusceptible to azithromycin and tetracycline. *In vitro* checkerboard experiments showed no occurrences of antagonism when testing gepotidacin in combination with a variety of currently used antimicrobial agents against *N. gonorrhoeae*. The PAE for gepotidacin that occurred when testing *N. gonorrhoeae* ranged from short to modest, with an extended PAE-SME observed for the two isolates tested.

Gepotidacin is a member of the new triazaacenaphthylene class of novel bacterial topoisomerase inhibitors (NBTIs) and inhibits both bacterial gyrase and topoisomerase IV. Gepotidacin and other mechanistically related (but structurally different) NBTIs have

**TABLE 4** PAE-SME results observed for time-kill curves for gepotidacin and comparator agents after 1 h of exposure at 5× MIC and addition of 0.25× MIC or 0.5× MIC of the antimicrobial agent

<i>N. gonorrhoeae</i> isolate	Gepotidacin			Ceftriaxone		
	5× MIC (μg/ml)	PAE-SME (h) at:		5× MIC (μg/ml)	PAE-SME (h) at:	
		5× MIC + 0.25× MIC	5× MIC + 0.5× MIC		5× MIC + 0.25× MIC	5× MIC + 0.5× MIC
ATCC 49226	1.25	>2.5	>2.5	0.02	0.5	0.1
12584	0.625	1.2	2.7	0.02	1.3	0.0

a mode of action which differs from fluoroquinolones in that they bind to the DNA-protein complex at a location that is away from the cleavage site and do not form a cleavage complex (12, 13). Since gepotidacin and NBTIs bind at a different location than fluoroquinolones, they have demonstrated *in vitro* activity against strains resistant to other antibacterial classes, including fluoroquinolones (7, 8).

Resistance frequencies for NBTIs have been previously reported for other organisms and were shown to be in the range of  $10^{-8}$  to  $10^{-10}$  (13–15). In our study, spontaneous mutations to gepotidacin in *N. gonorrhoeae* were not obtained for the strains tested; however, the experimental approach used to select for resistance was a method that would most likely identify single-step and not multistep mutations. Although in our study, with our methodology, the spontaneous single-step mutation rate for ciprofloxacin was low ( $10^{-9}$ ), others have reported rates of  $\sim 10^{-8}$  or that ciprofloxacin resistance was readily selected (16, 17). Further studies are needed to evaluate the relative development of resistance potential for gepotidacin compared to fluoroquinolones in the treatment of infections caused by *N. gonorrhoeae*.

These *in vitro* data demonstrating the attributes of gepotidacin, including potency, bactericidal activity, postantibiotic effect, and single-step resistance development, indicate that further study is warranted for potential use in treating infections caused by *N. gonorrhoeae*. Rapidly developing antimicrobial resistance in *N. gonorrhoeae* to all current treatment options for gonococcal infections means new therapies are urgently needed (5).

## MATERIALS AND METHODS

For all liquid *in vitro* assays described in the present study, testing was performed using FB (18).

*In vitro* broth microdilution methods were used to evaluate the MIC/MBC activity of gepotidacin and ceftriaxone (comparator agent) against 25 strains of *N. gonorrhoeae* (including five ciprofloxacin-nonsusceptible, five penicillin-nonsusceptible, five penicillin- and ciprofloxacin-nonsusceptible, and five azithromycin- or tetracycline-nonsusceptible strains) (9, 19). Quality control was tested daily for the broth microdilution method and inoculum density was monitored by colony counts for each test run. ATCC quality control strains were selected as appropriate for the conditions being tested and included *N. gonorrhoeae* ATCC 49226 (11). A drug was considered to exhibit bactericidal activity against a particular isolate when the MBC/MIC ratio was  $\leq 4$ .

For frequency of resistance development studies, three strains were tested by reference agar dilution MIC methods against gepotidacin plus the control agents, ciprofloxacin, ceftriaxone, azithromycin, and tetracycline (9). *N. gonorrhoeae* MS11 (ATCC BAA-1833) was provided by Ann Jerse, Uniformed Services University of the Health Sciences (Bethesda, MD). Based on the baseline agar dilution MIC results for gepotidacin, individual agar plates were prepared with  $4\times$  and  $8\times$  MIC values in duplicate for each of the three strains for both 0.1- and 1.0-ml inoculum volumes. Agar plates were inoculated and incubated at  $35^{\circ}\text{C}$  in 5%  $\text{CO}_2$  atmosphere for 24 and 48 h. Visible colonies of *N. gonorrhoeae* were quantitated and compared to the starting inoculum concentration to determine the mutation rate (i.e., calculated as the number of mutants/inoculum concentration).

For time-kill kinetics, gepotidacin and comparator agents were tested in FB at concentrations of  $0.25\times$ ,  $0.5\times$ ,  $1\times$ ,  $2\times$ ,  $4\times$ , and  $10\times$  MICs for each isolate and sampled at time zero hour ( $T_0$ ),  $T_2$ ,  $T_4$ ,  $T_8$ , and  $T_{24}$  (20). Time-kill curves were performed in duplicate. Bactericidal activity was defined as a  $\geq 3$ -log reduction in bacterial counts ( $\log_{10}$  CFU/ml). Three strains were used in these studies; including ATCC 49226 and fluoroquinolone-, tetracycline-, and azithromycin-nonsusceptible isolates.

Checkerboard synergy testing was performed by broth microdilution, as previously described (21). Gepotidacin was tested alone and in combination with moxifloxacin, levofloxacin, azithromycin, tetracycline, and ceftriaxone. The total fractional inhibitory concentration index ( $\Sigma\text{FIC}$ ) was scored as follows: synergy,  $\leq 0.5$ ; indifference,  $>0.5$  to  $\leq 4.0$ ; and antagonism,  $>4.0$ .

Gepotidacin was tested against isolates using time-kill methods to determine postantibiotic effect (PAE) and the PAE-sub-MIC effect (SME) (22–24). In addition to gepotidacin, ceftriaxone was tested as a comparator. The organisms were exposed for 1 h to gepotidacin or the comparison agent at  $1\times$ ,  $5\times$ , and  $10\times$  MICs as determined from broth microdilution testing for each agent. For the PAE-SME, only an initial  $5\times$  exposure was used; followed by  $0.25\times$  or  $0.5\times$  MIC reexposure. Antibacterials were removed by centrifugation at  $3,000 \times g$  for 3 min and resuspension of the cells in prewarmed media, followed by a 1:1,000 dilution in additional prewarmed media. Colony counts were performed at  $T_0$  (preantimicrobial exposure) and  $T_1$  (after antimicrobial exposure). Colony counts were taken immediately after antimicrobial removal and at each subsequent hour until visible turbidity was observed or up to 9 h.

## ACKNOWLEDGMENTS

This study was supported by GlaxoSmithKline (GSK; Collegeville, PA) and has been funded in whole or in part with federal funds from the Office of the Assistant Secretary

for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract HHSO100201300011C.

JMI Laboratories, Inc., also contracted to perform services in 2016 for Achaogen, Actelion, Allegra, Allergan, Ampliphi, API, Astellas, AstraZeneca, Basilea, Bayer, BD, Biomodels, Cardeas, CEM-102 Pharma, Cempra, Cidara, Cormedix, CSA Biotech, Cubist, Debiopharm, Dipexium, Duke, Durata, Entasis, Fortress, Fox Chase Chemical, Medpace, Melinta, Merck, Micurx, Motif, N8 Medical, Nabriva, Nexcida, Novartis, Paratek, Pfizer, Polyphor, Rempex, Scynexis, Shionogi, Spero Therapeutics, Symbal Therapeutics, Syn-olgoic, TGV Therapeutics, The Medicines Company, Theravance, ThermoFisher, Venatorx, Wockhardt, and Zavante. Some JMI employees are advisors/consultants for Allergan, Astellas, Cubist, Pfizer, Cempra, and Theravance. There are no speakers' bureaus or stock options to declare.

## REFERENCES

- Centers for Disease Control and Prevention. 2014. 2013 sexually transmitted disease surveillance. Centers for Disease Control and Prevention, Atlanta, GA.
- Fleming DT, Wasserheit JN. 1999. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect* 75:3–17. <https://doi.org/10.1136/sti.75.1.3>.
- Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. *MMWR Morb Mortal Wkly Rep* 56:332–336.
- Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. 2013. *Neisseria gonorrhoeae* treatment failure and susceptibility to cefixime in Toronto, Canada. *JAMA* 309:163–170. <https://doi.org/10.1001/jama.2012.176575>.
- Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. *MMWR Morb Mortal Wkly Rep* 61:590–594.
- Allen VG, Seah C, Martin I, Melano RG. 2014. Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in *Neisseria gonorrhoeae* in Ontario, Canada. *Antimicrob Agents Chemother* 58:2528–2534. <https://doi.org/10.1128/AAC.02608-13>.
- Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. *Nature* 466:935–940. <https://doi.org/10.1038/nature09197>.
- Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. 2016. *In vitro* activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. *Antimicrob Agents Chemother* 60:1918–1923. <https://doi.org/10.1128/AAC.02820-15>.
- Clinical and Laboratory Standards Institute. 2015. M07-A10: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK. 2016. Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for *Neisseria gonorrhoeae* ATCC 49226. *Antimicrob Agents Chemother* 60:4404–4406. <https://doi.org/10.1128/AAC.00527-16>.
- Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
- Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C. 2008. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. *Antimicrob Agents Chemother* 52:3339–3349. <https://doi.org/10.1128/AAC.00496-08>.
- Lahiri SD, Kutschke A, McCormack K, Alm RA. 2015. Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 59:5278–5287. <https://doi.org/10.1128/AAC.00571-15>.
- Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE. 2015. Target-based resistance in *Pseudomonas aeruginosa* and *Escherichia coli* to NBTI 5463, a novel bacterial type II topoisomerase inhibitor. *Antimicrob Agents Chemother* 59:331–337. <https://doi.org/10.1128/AAC.04077-14>.
- Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE. 2014. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. *Antimicrob Agents Chemother* 58:2657–2664. <https://doi.org/10.1128/AAC.02778-13>.
- Ruiz J, Jurado A, Garcia-Mendez E, Marco F, Aguilar L, Jimenez de Anta MT, Vila J. 2001. Frequency of selection of fluoroquinolone-resistant mutants of *Neisseria gonorrhoeae* exposed to gemifloxacin and four other quinolones. *J Antimicrob Chemother* 48:545–548. <https://doi.org/10.1093/jac/48.4.545>.
- Jeverica S, Golparian D, Hanzelka B, Fowlie AJ, Maticic M, Unemo M. 2014. High *in vitro* activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against *Neisseria gonorrhoeae* isolates with various high-level antimicrobial resistance and multidrug resistance. *J Antimicrob Chemother* 69:1866–1872. <https://doi.org/10.1093/jac/dku073>.
- Takei M, Yamaguchi Y, Fukuda H, Yasuda M, Deguchi T. 2005. Cultivation of *Neisseria gonorrhoeae* in liquid media and determination of its *in vitro* susceptibilities to quinolones. *J Clin Microbiol* 43:4321–4327. <https://doi.org/10.1128/JCM.43.9.4321-4327.2005>.
- Clinical and Laboratory Standards Institute. 1999. M26-A: methods for determining bactericidal activity of antimicrobial agents; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
- Leber AL (ed). 2016. Antimicrobial susceptibility testing, p. 5.16.1–5.16.21. *Clinical microbiology procedures handbook*, 4th ed. ASM Press, Washington, DC.
- Leber AL (ed). 2016. Antimicrobial susceptibility testing, p. 5.14.2.1–5.14.2.12. *Clinical microbiology procedures handbook*, 4th ed. ASM Press, Washington, DC.
- Odenholt-Tornqvist I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. *J Antimicrob Chemother* 31:881–892. <https://doi.org/10.1093/jac/31.6.881>.
- Odenholt-Tornqvist I, Lowdin E, Cars O. 1992. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. *Antimicrob Agents Chemother* 36:1852–1858. <https://doi.org/10.1128/AAC.36.9.1852>.
- Spangler SK, Lin G, Jacobs MR, Appelbaum PC. 1998. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. *Antimicrob Agents Chemother* 42:1253–1255.